FDA Approves Xenoview for Evaluating Lung Ventilation
The approval was based on data from 2 clinical trials that compared Xenoview MRI to xenon Xe 133 scintigraphy in adults with pulmonary disorders.
The approval was based on data from 2 clinical trials that compared Xenoview MRI to xenon Xe 133 scintigraphy in adults with pulmonary disorders.
The approval was based on data from the phase 3 ELUCIDATE study.
Gadopiclenol carries a Boxed Warning associated with an increased risk of nephrogenic systemic fibrosis among patients with impaired elimination of the drugs.
To address the ongoing COVID-19 related iodinated contrast media product shortage, Iomeron will be temporarily available in the US starting at the end of August 2022.
Due to COVID-19 related supply-chain disruptions, Iodixanol and other contrast media agents have been in shortage nationwide.
Visipaque and Omnipaque are radiographic contrast agents.
History of HSR to iodinated contrast media linked to increased risk for HSR to gadolinium-based contrast agent
The FDA has approved a new warning to the prescribing information for the entire class of ICM injections describing the risk of underactive thyroid or a temporary decrease in thyroid hormone levels.
The approval was based on data from a phase 2 trial that assessed Lymphoseek in pediatric patients with melanoma, RMS, or other solid tumors.
Pafolacianine sodium binds to folate receptors commonly found on many cancers, including ovarian and lung cancers, and illuminates the cancerous lesions under near-infrared light.